QuidelOrtho Corporation (QDEL)
NASDAQ: QDEL · Real-Time Price · USD
27.50
-0.64 (-2.27%)
At close: Nov 26, 2025, 4:00 PM EST
26.86
-0.64 (-2.34%)
After-hours: Nov 26, 2025, 7:22 PM EST
QuidelOrtho Revenue
QuidelOrtho had revenue of $699.90M in the quarter ending September 28, 2025, a decrease of -3.74%. This brings the company's revenue in the last twelve months to $2.71B, down -3.67% year-over-year. In the year 2024, QuidelOrtho had annual revenue of $2.78B, down -7.17%.
Revenue (ttm)
$2.71B
Revenue Growth
-3.67%
P/S Ratio
0.69
Revenue / Employee
$411,273
Employees
6,600
Market Cap
1.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 2.78B | -214.90M | -7.17% |
| Dec 31, 2023 | 3.00B | -268.20M | -8.21% |
| Jan 1, 2023 | 3.27B | 1.57B | 92.28% |
| Jan 2, 2022 | 1.70B | 36.90M | 2.22% |
| Jan 3, 2021 | 1.66B | 1.13B | 210.66% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
QDEL News
- 2 days ago - QuidelOrtho To Participate In Upcoming Investor Conferences - PRNewsWire
- 6 days ago - The Power of Prevention: Detecting Diabetes Before It Strikes - PRNewsWire
- 20 days ago - QuidelOrtho Corporation (QDEL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - QuidelOrtho Reports Third Quarter 2025 Financial Results - PRNewsWire
- 23 days ago - QuidelOrtho Receives FDA 510(k) Clearance for VITROS™ Immunodiagnostic Products hs Troponin I Assay - PRNewsWire
- 4 weeks ago - Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics - PRNewsWire
- 5 weeks ago - QuidelOrtho to Report Third Quarter 2025 Financial Results - PRNewsWire
- 5 weeks ago - QuidelOrtho Showcases Leadership in Transfusion Medicine at AABB 2025 - PRNewsWire